Breast Cancer
A multi-center, Phase 2 trial of afimoxifene gel vs. oral tamoxifen in women with ductal carcinoma in situ (DCIS) of the breast will be conducted by the National Cancer Prevention Group Consortium starting in the second quarter of 2009. This trial is being coordinated by the National Institutes of Health/National Cancer Institute.
To learn more about ASCEND's breast cancer research project, visit the website of our R&D affiliate BHR Pharma, LLC.